RecruitingPhase 1NCT07505771
A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer
A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Malignancies
Sponsor
Immunome, Inc.
Enrollment
105 participants
Start Date
Jun 19, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called 177Lu-IM-3050 for people with solid malignancies. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUG177Lu-IM-3050
177Lu-IM-3050 is a FAP-directed radiopharmaceutical
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07505771
Related Trials
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
NCT066007896 locations
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
NCT0682316722 locations
Theranostic PET for Target Validation and Tumor Detection
NCT076644101 location
Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)
NCT075384791 location
A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors
NCT0672538115 locations